2021 共识建议:玻璃体视网膜淋巴瘤的诊断

2021-05-19 国外肿瘤科相关专家小组(统称) Ocul Immunol Inflamm.2021 May 19;1-14.

玻璃体视网膜淋巴瘤(VRL)以前成为原发性眼内淋巴瘤,是一种罕见的眼内恶性肿瘤。本文主要针对玻璃体视网膜淋巴瘤的诊断提供共识建议。

中文标题:

2021 共识建议:玻璃体视网膜淋巴瘤的诊断

英文标题:

Consensus Recommendations for the Diagnosis of Vitreoretinal Lymphoma

发布日期:

2021-05-19

简要介绍:

玻璃体视网膜淋巴瘤(VRL)以前成为原发性眼内淋巴瘤,是一种罕见的眼内恶性肿瘤。本文主要针对玻璃体视网膜淋巴瘤的诊断提供共识建议。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=2021 共识建议:玻璃体视网膜淋巴瘤的诊断.pdf)] GetToolGuiderByIdResponse(projectId=1, id=471821c0021133a9, title=2021 共识建议:玻璃体视网膜淋巴瘤的诊断, enTitle=Consensus Recommendations for the Diagnosis of Vitreoretinal Lymphoma, guiderFrom=Ocul Immunol Inflamm.2021 May 19;1-14., authorId=0, author=, summary=玻璃体视网膜淋巴瘤(VRL)以前成为原发性眼内淋巴瘤,是一种罕见的眼内恶性肿瘤。本文主要针对玻璃体视网膜淋巴瘤的诊断提供共识建议。, cover=https://img.medsci.cn/2021618/1623989999954_2020535.jpg, journalId=0, articlesId=null, associationId=887, associationName=国外肿瘤科相关专家小组(统称), associationIntro=null, copyright=0, guiderPublishedTime=Wed May 19 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>玻璃体视网膜淋巴瘤(VRL)以前成为原发性眼内淋巴瘤,是一种罕见的眼内恶性肿瘤。本文主要针对玻璃体视网膜淋巴瘤的诊断提供共识建议。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=412, tagName=淋巴瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=32, categoryName=眼科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=412, guiderKeyword=淋巴瘤, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=12948, appHits=130, showAppHits=0, pcHits=1234, showPcHits=12818, likes=1, shares=12, comments=7, approvalStatus=1, publishedTime=Fri Jun 18 13:15:45 CST 2021, publishedTimeString=2021-05-19, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Fri Jun 18 12:20:14 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 22:45:05 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 共识建议:玻璃体视网膜淋巴瘤的诊断.pdf)])
2021 共识建议:玻璃体视网膜淋巴瘤的诊断.pdf
下载请点击:
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1207289, encodeId=f0d3120e28923, content=学习了!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a9c3997331, createdName=139ef189m47暂无昵称, createdTime=Wed Mar 30 18:49:01 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064817, encodeId=dc79106481eed, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Thu Oct 28 21:48:30 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053520, encodeId=ebf71053520aa, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d355585859, createdName=ms8000000444017043, createdTime=Tue Sep 21 16:19:25 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004117, encodeId=9c87100411e2a, content=收益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44565409552, createdName=眼科芳, createdTime=Fri Jul 30 23:55:04 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003916, encodeId=c4d010039164d, content=受益了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/3bf2334e50604c0a86fdd028570a8bdc/ebee9ab0697b40f3b72b68fa7c659ee7.jpg, createdBy=6d582405709, createdName=站在未来看现在, createdTime=Fri Jul 30 16:06:34 CST 2021, time=2021-07-30, status=1, ipAttribution=)]
    2022-03-30 139ef189m47暂无昵称

    学习了!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1207289, encodeId=f0d3120e28923, content=学习了!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a9c3997331, createdName=139ef189m47暂无昵称, createdTime=Wed Mar 30 18:49:01 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064817, encodeId=dc79106481eed, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Thu Oct 28 21:48:30 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053520, encodeId=ebf71053520aa, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d355585859, createdName=ms8000000444017043, createdTime=Tue Sep 21 16:19:25 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004117, encodeId=9c87100411e2a, content=收益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44565409552, createdName=眼科芳, createdTime=Fri Jul 30 23:55:04 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003916, encodeId=c4d010039164d, content=受益了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/3bf2334e50604c0a86fdd028570a8bdc/ebee9ab0697b40f3b72b68fa7c659ee7.jpg, createdBy=6d582405709, createdName=站在未来看现在, createdTime=Fri Jul 30 16:06:34 CST 2021, time=2021-07-30, status=1, ipAttribution=)]
    2021-10-28 245462683

    学习学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1207289, encodeId=f0d3120e28923, content=学习了!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a9c3997331, createdName=139ef189m47暂无昵称, createdTime=Wed Mar 30 18:49:01 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064817, encodeId=dc79106481eed, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Thu Oct 28 21:48:30 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053520, encodeId=ebf71053520aa, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d355585859, createdName=ms8000000444017043, createdTime=Tue Sep 21 16:19:25 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004117, encodeId=9c87100411e2a, content=收益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44565409552, createdName=眼科芳, createdTime=Fri Jul 30 23:55:04 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003916, encodeId=c4d010039164d, content=受益了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/3bf2334e50604c0a86fdd028570a8bdc/ebee9ab0697b40f3b72b68fa7c659ee7.jpg, createdBy=6d582405709, createdName=站在未来看现在, createdTime=Fri Jul 30 16:06:34 CST 2021, time=2021-07-30, status=1, ipAttribution=)]
    2021-09-21 ms8000000444017043

    学习学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1207289, encodeId=f0d3120e28923, content=学习了!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a9c3997331, createdName=139ef189m47暂无昵称, createdTime=Wed Mar 30 18:49:01 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064817, encodeId=dc79106481eed, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Thu Oct 28 21:48:30 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053520, encodeId=ebf71053520aa, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d355585859, createdName=ms8000000444017043, createdTime=Tue Sep 21 16:19:25 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004117, encodeId=9c87100411e2a, content=收益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44565409552, createdName=眼科芳, createdTime=Fri Jul 30 23:55:04 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003916, encodeId=c4d010039164d, content=受益了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/3bf2334e50604c0a86fdd028570a8bdc/ebee9ab0697b40f3b72b68fa7c659ee7.jpg, createdBy=6d582405709, createdName=站在未来看现在, createdTime=Fri Jul 30 16:06:34 CST 2021, time=2021-07-30, status=1, ipAttribution=)]
    2021-07-30 眼科芳

    收益

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1207289, encodeId=f0d3120e28923, content=学习了!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a9c3997331, createdName=139ef189m47暂无昵称, createdTime=Wed Mar 30 18:49:01 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064817, encodeId=dc79106481eed, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df621297957, createdName=245462683, createdTime=Thu Oct 28 21:48:30 CST 2021, time=2021-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053520, encodeId=ebf71053520aa, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d355585859, createdName=ms8000000444017043, createdTime=Tue Sep 21 16:19:25 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004117, encodeId=9c87100411e2a, content=收益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44565409552, createdName=眼科芳, createdTime=Fri Jul 30 23:55:04 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003916, encodeId=c4d010039164d, content=受益了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/3bf2334e50604c0a86fdd028570a8bdc/ebee9ab0697b40f3b72b68fa7c659ee7.jpg, createdBy=6d582405709, createdName=站在未来看现在, createdTime=Fri Jul 30 16:06:34 CST 2021, time=2021-07-30, status=1, ipAttribution=)]
    2021-07-30 站在未来看现在

    受益了

    0

拓展阅读

2010 ACR 霍奇金淋巴瘤临床I期和II期的放疗

美国放射学会(ACR,American College of Radiology) · 2010-01-01

2010 BCSH 淋巴瘤诊断报告最佳实践指南

英国血液学标准委员会(BCSH,British Committee for Standards in Haematology) · 2010-04-01

ESMO临床诊疗指南:弥漫大B细胞非霍奇金淋巴瘤(2010)

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2010-05-21

2011 ESMO临床诊疗指南:新诊断和复发性滤泡性淋巴瘤的诊断、治疗与随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2011-01-01

2011 ESMO霍奇金淋巴瘤临床诊疗指南

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2011-01-01

2011 中国儿童非霍奇金淋巴瘤诊疗建议

中华医学会儿科学分会血液学组 · 2011-03-01